affymetrix

Piper Jaffray is out with its report today on Affymetrix (NASDAQ: AFFX), maintaining Neutral. In a note to clients, Piper Jaffray writes, "Affymetrix announced preliminary 2Q11 top-line results, with total revenue anticipated to be in the $64M-$65M range, below our previous $75.3M and Street...

Oppenheimer is out with its report on Affymetrix (NASDAQ: AFFX), maintaining Perform. In a note to clients, Oppenheimer writes, "Today, AFFX announced the appointment of Dr. Frank Witney as president and CEO effective July 1, 2011. Dr. Witney will replace Kevin M. King, who successfully improved...

Goldman Sachs has changed the price targets on the following companies: Affymetrix (NASDAQ: AFFX) from $4.50 to $5, Sell Bank of New York Mellon (NYSE: BK) from $30 to $29, Neutral Baxter International (NYSE: BAX) from $69 to $72, Buy CME Group (NASDAQ: CME) from $345 to $325, Neutral...

In a recent report by Oppenheimer, it gave a quarterly update for Affymetrix Inc. (NASDAQ: AFFX) following the release of AFFX's 1Q earnings. According to Oppenheimer, Affymetrix experienced negative revenue growth but were close to forecast expectations. Oppenheimer explains, “1Q11 revenue of $73...

Oppenheimer initiating coverage of Affymetrix Inc. (NASDAQ: AFFX) with a Perform rating. “Affymetrix is a life science tools company primarily known for its microarray franchise,” Oppenheimer writes. “Recently, the company has begun a diversification strategy to reduce its reliance on traditional...

Deutsche Bank has published a research report on Healthcare Services & Technology after President Obama released details on his FY2012 budget this morning. In the report, Deutsche Bank writes "The budget is primarily focused on deficit reduction, but the budget for the NIH was actually provided...

JP Morgan has downgraded Affymetrix (NASDAQ: AFFX) from Neutral to Underweight.

Jefferies & Co. has published a research report for Life Sciences, reporting: "Median short interest for listed and OTC Life Science Research Supply stocks rose 1% from the second half of August, while aggregate short interest levels were essentially unchanged (vs. a 1% increase for Nasdaq and...